特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
778273

世界の肝臓癌治療薬市場:2019~2023年

Global Liver Cancer Drugs Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 107 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
世界の肝臓癌治療薬市場:2019~2023年
出版日: 2019年01月09日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 107 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の肝臓癌治療薬市場は2023年までにCAGR%10で拡大すると予測されています。脂肪肝などの生活習慣病の発症率上昇が肝臓癌の主なリスクファクターになっています。

当レポートでは、世界の肝臓癌治療薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 市況

  • 市場エコシステム
  • 市場特性
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 2018年の市場規模
  • 市場規模と予測:2018~2023年

第6章 ファイブフォース分析

第7章 タイプ別市場セグメンテーション

  • 市場セグメンテーション
  • 比較
  • 免疫療法
  • 標的療法
  • 市場の機会

第8章 消費者動向

第9章 地域別動向

  • 地域別セグメンテーション
  • 比較
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域
  • 主要国
  • 市場の機会

第10章 市場促進因子と阻害因子

第11章 市場動向

第12章 ベンダー環境

第13章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • 市場ポジショニング
  • Bayer
  • Bristol-Myers Squibb
  • エーザイ株式会社
  • Merck
  • 小野薬品工業株式会社

第14章 付録

図表
  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Segments of global oncology therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Late-stage pipeline drugs for liver cancer
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Immunotherapy - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 22: Immunotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Targeted therapy - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 24: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: Americas - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: APAC - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Key leading countries
  • Exhibit 36: Market opportunity
  • Exhibit 37: Decision framework
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: Bayer - Vendor overview
  • Exhibit 45: Bayer - Business segments
  • Exhibit 46: Bayer - Organizational developments
  • Exhibit 47: Bayer - Geographic focus
  • Exhibit 48: Bayer - Segment focus
  • Exhibit 49: Bayer - Key offerings
  • Exhibit 50: Bristol-Myers Squibb - Vendor overview
  • Exhibit 51: Bristol-Myers Squibb - Business segments
  • Exhibit 52: Bristol-Myers Squibb - Organizational developments
  • Exhibit 53: Bristol-Myers Squibb - Geographic focus
  • Exhibit 54: Bristol-Myers Squibb - Key offerings
  • Exhibit 55: Eisai - Vendor overview
  • Exhibit 56: Eisai - Business segments
  • Exhibit 57: Eisai - Organizational developments
  • Exhibit 58: Eisai - Geographic focus
  • Exhibit 59: Eisai - Segment focus
  • Exhibit 60: Eisai - Key offerings
  • Exhibit 61: Merck - Vendor overview
  • Exhibit 62: Merck - Business segments
  • Exhibit 63: Merck - Organizational developments
  • Exhibit 64: Merck - Geographic focus
  • Exhibit 65: Merck - Segment focus
  • Exhibit 66: Merck - Key offerings
  • Exhibit 67: Ono Pharmaceutical - Vendor overview
  • Exhibit 68: Ono Pharmaceutical - Business segments
  • Exhibit 69: Ono Pharmaceutical - Organizational developments
  • Exhibit 70: Ono Pharmaceutical - Geographic focus
  • Exhibit 71: Ono Pharmaceutical - Key offerings
  • Exhibit 72: Validation techniques employed for market sizing
  • Exhibit 73: List of abbreviations
目次
Product Code: IRTNTR30608

About this market:

Liver cancer is among the leading causes of cancer-related deaths, globally. The increase in incidence of risk factors like hepatitis B and C and underlying cirrhosis will lead to the rise in risk of liver cancer depending on the etiology. The increase in incidence of life-style diseases like fatty liver is a major risk factor for liver cancer. Furthermore, the increase in incidence of new risk factors like diabetes, obesity, and related non-alcoholic fatty liver disease may also be associated with the increase in incidence of liver cancer. The current disease management for liver cancer is the same for all patients with different etiologies. Advances in disease management for the causative factors may reduce the incidence of liver cancer. Technavio's analysts have predicted that the liver cancer drugs market will register a CAGR of over 10% by 2023.

Market Overview:

Advancements in diagnostics methods

Long-term survival requires advanced diagnostic methods, which may detect small tumors that are often present in asymptomatic patients. Elevated levels of the serum marker alfa-fetoprotein are often indicative of the disease when combined with ultrasonography. Liver biopsy is also a diagnostic method used by many professionals. Various serologic markers may help to improve surveillance accuracy. Computed tomography and magnetic resonance imaging are currently used for liver imaging for surveillance. However, they can be used for the diagnosis and staging of liver cancer.

Only curative option is surgical resection and transplantation

The surgery is often associated with high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation. However, a major challenge for liver transplantation is the number of insufficient donor livers. Another challenge is that the disease is often diagnosed in the advanced stage when surgery or transplantation may not be feasible.

For the detailed list of factors that will drive and challenge the growth of the liver cancer drugs market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Immunotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • Merck
  • Ono Pharmaceutical

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.